Teva to sell 79 drugs to gain approval for Allergan’s generic business

Teva Pharmaceutical Industries will sell the rights and assets related to 79 pharmaceutical products to settle the government’s anticompetitive claims surrounding its $40.5 billion purchase of Allergan’s generic drug business. The divestiture, which is subject to a 30-day public comment period, is the largest in history. The products include anesthetics,